Literature DB >> 12660527

Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations.

Katharina Skrabal1, Virginie Trouplin, Béatrice Labrosse, Véronique Obry, Florence Damond, Allan J Hance, François Clavel, Fabrizio Mammano.   

Abstract

OBJECTIVE: To study the impact of antiretroviral therapy on the tropism of plasma HIV-1 virus populations during treatment response and virological escape.
DESIGN: To investigate whether the selective pressure exerted by antiretroviral treatment influences the tropism of the plasma virus populations, we retrospectively determined the co-receptor usage of viruses present in plasma samples obtained before and at varying intervals after starting antiviral therapy.
METHODS: The co-receptor usage of plasma virus was determined using our recently published tropism recombinant test (V. Trouplin et al., J Virol, 2001; 75:251-259). This assay relies on virus production by homologous recombination between a plasmid encoding the entire HIV genome except for a deletion of the major tropism determinant, and a polymerase chain reaction (PCR) product spanning this region and the adjoining flanking sequences, obtained by reverse transcriptase (RT)-PCR amplification of viral RNA from the patient's plasma.
RESULTS: Twenty-four of the 32 patients analysed harboured exclusively R5 virus in plasma before the initiation of treatment, whereas eight had mixed R5/X4 virus populations. In four of these eight patients, all of whom initially responded to treatment, the persistence of R5 virus in plasma was observed, whereas the X4 component of the virus population became undetectable. The suppression of the X4 virus component was a transient phenomenon and variants able to use CXCR4 re-emerged after a variable delay.
CONCLUSIONS: The impact of therapy on virus populations differs according to virus tropism. Differences in target cell populations, tissue distribution and replication characteristics between R5 and X4 viruses could explain the preferential suppression of X4 virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660527     DOI: 10.1097/00002030-200304110-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  Persistence and emergence of X4 virus in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson
Journal:  Math Biosci Eng       Date:  2011-04       Impact factor: 2.080

2.  Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.

Authors:  Ruy M Ribeiro; Mette D Hazenberg; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.

Authors:  Katharina Skrabal; Sentob Saragosti; Jean-Louis Labernardière; Francis Barin; François Clavel; Fabrizio Mammano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Risk of breast cancer with CXCR4-using HIV defined by V3 loop sequencing.

Authors:  James J Goedert; Luke C Swenson; Laura A Napolitano; Mojgan Haddad; Kathryn Anastos; Howard Minkoff; Mary Young; Alexandra Levine; Oluwatoyin Adeyemi; Eric C Seaberg; Bradley Aouizerat; Charles S Rabkin; P Richard Harrigan; Nancy A Hessol
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

6.  Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.

Authors:  Diana M Brainard; William G Tharp; Elva Granado; Nicholas Miller; Alicja K Trocha; Xiang-Hui Ren; Brian Conrad; Ernest F Terwilliger; Richard Wyatt; Bruce D Walker; Mark C Poznansky
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Authors:  Sarah K Ho; Elena E Perez; Stephanie L Rose; Roxana M Coman; Amanda C Lowe; Wei Hou; Changxing Ma; Robert M Lawrence; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

8.  Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study.

Authors:  James C Shepherd; Lisa P Jacobson; Wei Qiao; Beth D Jamieson; John P Phair; Paolo Piazza; Thomas C Quinn; Joseph B Margolick
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

9.  Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Authors:  Jeffrey M Jacobson; Robert J Israel; Israel Lowy; Nancy A Ostrow; Linda S Vassilatos; Melanie Barish; Diep N H Tran; Brian M Sullivan; Thomas J Ketas; Tobias J O'Neill; Kirsten A Nagashima; Wei Huang; Christos J Petropoulos; John P Moore; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Characterization of peripheral blood human immunodeficiency virus isolates from Hispanic women with cognitive impairment.

Authors:  Dianedis M Toro Nieves; Marinés Plaud; Valerie Wojna; Richard Skolasky; Loyda M Meléndez
Journal:  J Neurovirol       Date:  2007-08       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.